Creyon Bio applies purpose-built data sets to drive efficient creation of machine learning models to engineers oligonucleotide-based medicines (OBMs) for safe, precise gene-centric therapies with unprecedented speed and predictable efficacy and safety.
Total raised: $40M
Investors 3
| Date | Name | Website |
| 19.03.2022 | DCVC | dcvc.com/ |
| - | Biobrit | biobrit.co... |
| 11.03.2022 | Lux Capita... | luxcapital... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 09.03.2022 | Seed | $40M | - |
Mentions in press and media 4
| Date | Title | Description | Source |
| 09.03.2022 | Creyon Bio receives $40M in Seed and Series A funding to fut... | - | connect.or... |
| 09.03.2022 | Creyon Bio secures $40M | Creyon Bio has raised $40 million in seed and Series A financing co-led by DCVC Bio and Lux Capital.... | pitchbook.... |
| 09.03.2022 | Creyon Bio Gets $40M For Precision Medicine | San Diego- and Research Triangle Park, NC-based Creyon Bio said Tuesday that it has raised $40M in a... | socaltech.... |
| 08.03.2022 | Creyon Bio Secures $40M in Seed and Series A Financing | Creyon Bio, a San Diego, CA and Research Triangle Park, NC-based drug development company, raised $4... | finsmes.co... |